Abstract: Also known as CD169 or sialoadhesin (Sn), SIGLEC1 is predominantly expressed on the surfaces of some special macrophage subsets, dendritic cells and T lymphocytes. After recognizing and binding to ligands on the surface of other cells, it participates in pathophysiological processes through cell-cell interaction, including antigen presentation, lymphocyte proliferation, immune response and tolerance, phagocytosis, viral infection and inflammatory responses. And it plays vital roles in the occurrence and development of human diseases including autoimmune, infectious, inflammatory diseases and tumors. This review focused upon the current research status of SIGLEC1 in renal diseases. It may become a biomarker of reflecting the activity, severity and prognosis of renal diseases and provide a novel therapeutic target for certain renal diseases.